Solventum beats quarterly estimates on strong demand for surgical products

Feb 26 (Reuters) – Medical device maker Solventum on Thursday beat Wall Street estimates for the fourth quarter, helped by strong demand for its wound care and sterilization products.

The Minnesota-based company is one of the largest providers of sterilization devices, wound dressings, medical tape and other hospital consumables. 

Solventum’s MedSurg business, which sells wound dressings and surgical equipment, accounts for more than half the company’s revenue. Sales in the segment rose 5.2% from a year earlier to $1.24 billion during the quarter.

The company’s quarterly revenue came in at $2 billion, beating analysts’ estimates of $1.96 billion, according to data compiled by LSEG.

On an adjusted basis, it earned a profit of $1.57 per share, compared with estimates of $1.50 per share.

“Solventum’s fourth quarter results reflect another quarter of solid performance resulting in full year 2025 results ahead of our expectations for sales and EPS,” said CEO Bryan Hanson.

The company also forecast 2026 adjusted profit above Wall Street expectations at $6.40 to $6.60 per share, compared with estimates of $6.34 per share.

Last year, Solventum said it would acquire privately held Acera Surgical for up to $850 million, expanding its wound care portfolio by gaining access to Restrata, a synthetic treatment option for soft tissue repair.

The deal would be slightly dilutive to adjusted earnings per share in 2026, but accretive beginning in 2027, Solventum had said.

The company also unveiled a four-year program in 2025 to boost growth, which is expected to deliver about $500 million in annual savings once fully implemented.

(Reporting by Sneha S K Bengaluru; Editing by Jonathan Ananda)